Platelet Function Analysis: Nursing Guide
Platelet function analysis — often performed on a PFA-100 or similar analyzer — measures how quickly platelets form a plug under high shear using collagen/epinephrine (CEPI) and collagen/ADP (CADP) membranes. Nurses support valid citrated whole blood collection within the laboratory time window, document antiplatelet and NSAID use, verify paired platelet count and hematocrit, and help teams interpret prolonged closure times without clearing invasive care when mucosal bleeding persists.
Contents
Quick Facts
Key Takeaway
Closure-time platelet function screening answers whether primary hemostasis looks impaired on CEPI and CADP cartridges — but results are valid only with adequate platelet count and hematocrit, timely non-centrifuged transport, and honest.
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Light blue top
3.2% sodium citrate — whole blood must remain non-centrifuged for PFA testing
Citrated whole blood (non-centrifuged) for PFA-100 or equivalent
Typically about 5 mL citrated whole blood per institutional protocol — tube filled to manufacturer mark; underfilled tubes may be rejected
Collect when ordered for bleeding workup or preprocedure screening; perform testing on whole blood within approximately 3–4 hours of draw per reviewed laboratory references; document recent aspirin, NSAID, and antiplatelet use on the requisition
No test preparation is usually required
Deliver citrated whole blood to the laboratory promptly at room temperature per local policy — do not centrifuge or refrigerate for standard PFA-100 workflows described in reviewed references
Often same day when the specimen arrives within the laboratory stability window; confirmatory aggregation or von Willebrand assays may take additional days
Coagulation / special hematology laboratory
What is Platelet Function Analysis?
Platelet Function Analysis is an in vitro laboratory screen of platelet-related primary hemostasis, commonly performed on a platelet function analyzer (PFA-100 or PFA-200). Citrated whole blood is aspirated through capillary cartridges coated with collagen plus epinephrine (CEPI) or collagen plus ADP (CADP). The instrument records closure time — seconds until platelets occlude a central aperture — as a surrogate for platelet plug formation under high shear, per Royal College of Pathologists of Australasia (RCPA) and Clinical and Laboratory Standards Institute (CLSI) platelet testing guidance cited in specialty reviews.
Overview
Ward nurses most often see platelet function analysis during unexplained bruising, gum bleeding, heavy menstrual bleeding workups, or before dental extraction, endoscopy, or surgery when automated CBC and clotting screens do not explain symptoms. The assay runs in the laboratory on fresh citrated whole blood — nurses ensure specimen integrity, medicine documentation, and timely transport while results are pending.
Because thrombocytopenia, anemia, recent aspirin or NSAIDs, and von Willebrand disease can prolong closure times, results must be read with symptoms, platelet count, hematocrit, and the reporting laboratory comment. Prolonged CEPI with normal CADP often fits aspirin effect; both cartridges prolonged may suggest broader platelet dysfunction or von Willebrand factor problems — follow-up von Willebrand factor assays and hematology input are common next steps.
Before collection, confirm paired platelet count and hematocrit are available or ordered, use a completely filled citrate tube with a 21-gauge or larger needle when policy allows, avoid butterfly or line draws that add shear artifact when possible, and list aspirin, clopidogrel, NSAIDs, and supplements on the requisition. After results return, communicate closure-time patterns with bleeding history — never tell patients a single normal cartridge alone clears surgery when mucosal bleeding continues.
Antiplatelet Medicine and Specimen Validity Safety
Closure-time platelet function screening is only as trustworthy as the citrated whole blood underneath it. Hidden aspirin or NSAID use, thrombocytopenia, anemia, delayed transport, and line draws can prolong CEPI or CADP — or invalidate the run entirely — while teams still clear dental or surgical care.
- Active mucosal bleeding or falling hemoglobin while PFA is pending
- Both CEPI and CADP prolonged with neuraxial anaesthesia, major surgery, or dental extraction scheduled
- Platelet count or hematocrit below laboratory validity thresholds driving procedure clearance
- Clotted, underfilled, centrifuged, or stability-breached specimen used for bleeding-risk decisions
Document: CEPI and CADP values, paired CBC, medicine history, collection-to-lab time, prescriber notifications, procedure hold status, pending von Willebrand or aggregation assays, and bleeding teaching.
What Platelet Function Analysis Can and Cannot Tell You
This test can help identify:
- Screening impairment of platelet-related primary hemostasis on CEPI and CADP cartridges
- Suspected aspirin or aspirin-like drug effect (often CEPI prolonged, CADP normal)
- Need for von Willebrand factor or platelet aggregation confirmatory testing after abnormal patterns
- Whether routine platelet count alone explains bleeding symptoms
This test cannot:
- Diagnose von Willebrand disease or specific platelet storage-pool defects by itself
- Reliably monitor clopidogrel or other P2Y12 inhibitors per reviewed references
- Replace clinical bleeding assessment or clear surgery without hematology input
- Be interpreted reliably when platelet count, hematocrit, or specimen handling is invalid
Citrated Whole Blood and Antiplatelet Review Before PFA
Verify
Two identifiers match order and citrate labels
Platelet count and hematocrit meet laboratory validity rules
Aspirin, NSAIDs, P2Y12 inhibitors, supplements on requisition
Light-blue citrate filled to mark; gentle inversion; not centrifuged
21-gauge or larger peripheral needle when policy avoids butterfly or line draws
Whole blood to laboratory within about 3–4 hours per institutional protocol
Clarify before proceeding when:
- Order lacks bleeding history or preprocedure indication documented
- Platelet count or hematocrit below laboratory testing thresholds
- Patient took undisclosed aspirin or NSAIDs and repeat testing needs prescriber-guided holds
- Elective invasive procedure is scheduled before valid PFA returns
- Prior citrate specimen rejected for clot, underfill, or stability breach
- Active gum, nose, or GI bleeding is present without escalation plan
CEPI, CADP, and Closure-Time Patterns Nurses Should Know
RCPA and specialty reviews describe interpreting CEPI (collagen/epinephrine) and CADP (collagen/ADP) together with platelet count, hematocrit, and medicine history. Reference intervals are laboratory-specific — never use generic seconds cut-offs without the reporting range.
| Reported pattern | What it may suggest (per reviewed references) | Nursing focus |
|---|---|---|
| CEPI and CADP within reference | Primary hemostasis screen within expected limits — many significant defects less likely when CEPI normal | Document with symptoms; teach report-now bleeding; proceed per prescriber only when history benign |
| CEPI prolonged, CADP normal | Aspirin or aspirin-like drugs, mild von Willebrand disease, mild thrombocytopenia, or anemia | Medicine review; hold elective procedures until hematology or prescriber plan documented |
| CEPI and CADP both prolonged | Broader platelet dysfunction, von Willebrand abnormality, cytopenia, or combined medicine effect | Urgent prescriber and hematology communication; bleeding precautions; confirmatory assays |
| Testing not performed or invalid | Low platelets, low hematocrit, clot, underfill, or stability window breach | Recollect with paired CBC; do not use prior normal PFA to clear procedures |
PFA-100 is relatively sensitive to aspirin on CEPI but has variable and often poor sensitivity to clopidogrel per peer-reviewed laboratory reviews — do not use closure times alone to confirm or rule out P2Y12 inhibition.
Stability Window, Aspirin Traps, and CBC Pairing at the Bedside
| Bedside point | Nursing note |
|---|---|
| Whole blood only | Do not centrifuge citrate for standard PFA workflows — laboratory runs fresh whole blood |
| Four-hour window | Track collection time; delayed delivery invalidates or skews closure times |
| Aspirin pattern trap | CEPI prolonged with normal CADP still needs prescriber clearance before dental care |
| Clopidogrel trap | Normal PFA does not prove P2Y12 blockade — follow antiplatelet orders, not PFA alone |
| CBC pairing | Always chart closure times with same-day platelet count and hematocrit |
| Evaluate outcomes | Reassess gum bleeding after precautions — improved symptoms do not clear abnormal confirmatory workup alone |
Why Platelet Function Analysis is Ordered
Platelet function analysis is ordered when clinicians need a practical screen of primary hemostasis — especially when bleeding history and routine coagulation testing do not fully explain symptoms.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Unexplained mucocutaneous bleeding or easy bruising | Is primary hemostasis impaired despite normal platelet count on CBC? | RCPA and MLO Online describe PFA screening for patients who bruise easily or bleed excessively when platelet number appears adequate. |
| Suspected von Willebrand disease or inherited platelet disorder | Does closure-time screening support von Willebrand factor or platelet defect workup? | PFA assays are sensitive to von Willebrand factor defects; normal CEPI can exclude many significant platelet-related defects per RCPA, but confirmatory testing still follows abnormal patterns. |
| Preoperative or pre-dental procedure bleeding-risk assessment | Can elective invasive care proceed when closure times and symptoms are reviewed? | Laboratory medicine reviews note preprocedure testing in selected patients — nurses coordinate holds and specialist clearance rather than interpreting closure times alone. |
| Assessment of recent antiplatelet exposure (especially aspirin) | Does CEPI prolongation with normal CADP fit aspirin or NSAID effect? | Aspirin and aspirin-like drugs preferentially prolong CEPI closure time while CADP may remain normal per RCPA and ClinLab Navigator — PFA-100 is relatively insensitive to clopidogrel in reviewed references. |
Contraindications and Precautions
There is no absolute contraindication to venous blood collection, but PFA testing may be invalid or not performed when platelet count or hematocrit falls below laboratory thresholds, when specimens are clotted or underfilled, or when testing cannot occur within the required whole-blood stability window per manufacturer and RCPA guidance.
- Active mucosal bleeding, falling hemoglobin, or hemarthrosis while PFA is pending — escalate clinically without waiting for closure times.
- Platelet count or hematocrit below laboratory validity thresholds — result may be unreliable; repeat CBC and recollect before procedure clearance.
- Specimen drawn through heparinized line, clotted, or received after stability window — recollect before bleeding-risk decisions.
- Assuming normal CADP clears surgery when CEPI is prolonged and patient still takes aspirin — prescriber and hematology must guide holds.
- Using PFA to monitor clopidogrel effect — reviewed references state variable and often poor sensitivity for P2Y12 inhibitors.
- Ignoring anemia or thrombocytopenia that artifactually prolong closure time — always pair with same-day CBC.
- Hemodynamic change, large bruises, or uncontrolled gum or nose bleeding with prolonged closure times or pending PFA.
- Both CEPI and CADP markedly prolonged with planned invasive procedure in 48 hours — prescriber and hematology review before proceeding.
- Laboratory rejects specimen for clots, underfill, or stability breach — recollect and hold elective procedures until valid results return.
Patient Preparation
Preparation focuses on medicine history, paired hematology values, and specimen handling that preserves whole-blood validity. Many laboratories advise avoiding NSAIDs for about 48 hours and aspirin-containing products for up to 10 days before elective testing when clinically safe — follow prescriber instructions, not independent holds.
Pre-test checksReview aspirin, clopidogrel, ticagrelor, prasugrel, NSAIDs (ibuprofen, naproxen), selective serotonin reuptake inhibitors when relevant, and fish oil or vitamin E supplements. RCPA and laboratory manuals note aspirin prolongs CEPI; NSAIDs may interfere with aspirin effect in some patients per peer-reviewed reviews. Document holds per prescriber — do not stop antiplatelet medicines independently.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Platelet Function Analysis. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Results report closure times in seconds for CEPI and CADP cartridges compared with institutional reference intervals. RCPA cites guide intervals (laboratory-specific) such as CADP about 70–124 seconds and CEPI about 90–160 seconds — always use the reporting laboratory range. Nurses communicate patterns and pending confirmatory tests; hematology interprets definitive bleeding disorders.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within expected range or therapeutic target | CEPI and CADP closure times within institutional reference interval | Primary hemostasis screen within expected limits — many significant platelet function defects including severe von Willebrand disease are less likely when CEPI is normal per RCPA, but clinical context still matters | Document values with symptoms; proceed with planned care only per prescriber when bleeding history is benign — teach report-now bleeding signs |
| Near therapeutic target / borderline | Borderline prolongation on one or both cartridges per laboratory comment | May reflect mild anemia, low-normal platelets, recent medicine exposure, or early von Willebrand abnormality — not a definitive label alone | Notify prescriber; clarify medicines and repeat testing or von Willebrand panel per orders; avoid automatic procedure clearance |
| Prolonged / above target | Prolonged CEPI and/or CADP closure time above reference | Suggests platelet dysfunction, von Willebrand factor abnormality, thrombocytopenia, anemia, or antiplatelet effect depending on cartridge pattern per RCPA and ClinLab Navigator | Notify prescriber and hematology; hold elective invasive procedures until workup completes; bleeding precautions and confirmatory assays per protocol |
| Shortened / below target | Shortened closure time below reference (uncommon) | Not commonly specified in reviewed nursing references — follow laboratory comment and correlate with thrombosis risk only per specialist guidance | Document value; clarify with laboratory and prescriber before changing antiplatelet therapy |
Closure-Time Patterns, Bleeding Escalation, and Procedure Holds
Universal numeric critical values for platelet function closure times are not specified in published references. Escalation is driven by active bleeding, invalid specimens, and prolonged patterns before high-risk procedures.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Active bleeding with prolonged or pending PFA | Mucosal hemorrhage, large hematoma, or hemodynamic change | Escalate according to facility policy; initiate bleeding pathway — do not delay for closure-time reporting alone |
| Both cartridges prolonged before invasive care | CEPI and CADP closure times above reference with surgery or dental extraction scheduled | Notify prescriber and hematology; hold elective procedure until von Willebrand and platelet aggregation workup documented |
| Invalid specimen or excluded testing | Low platelets, low hematocrit, clot, underfill, or stability window breach | Recollect with paired CBC; document rejection; do not use prior normal PFA to clear procedures |
Stop routine workflow and escalate according to facility policy when the patient has uncontrolled bleeding, both closure times prolonged with imminent invasive care, invalid specimens driving procedure decisions, or symptoms that conflict with reassuring cartridge results.
Factors Affecting Results
Closure times change with hematology values, collection technique, timing, and medicines. Question unexpected patterns before clearing procedures.
- Prolonged closure from anemia or thrombocytopenia misread as intrinsic platelet defect — repeat CBC first
- CEPI prolongation from undisclosed aspirin interpreted as von Willebrand disease without medicine review
- Normal CADP reassuring team while CEPI remains prolonged and patient still bleeds on brushing
- Normal CEPI assumed to exclude all bleeding disorders — mild platelet defects or storage pool disease may need aggregation studies per hematology
- Normal PFA while on clopidogrel — test is relatively insensitive to P2Y12 inhibition in reviewed references
- Delayed transport beyond stability window producing falsely normal or invalid results
- Thrombocytopenia and low hematocrit
- Aspirin, NSAIDs, and other antiplatelet agents
- Butterfly needles, line draws, clotted samples, and delayed delivery beyond 3–4 hours
PFA closure-time screening does not replace platelet aggregation studies, does not reliably monitor clopidogrel, and is invalid with low platelet count or hematocrit per reviewed laboratory references. Results vary by analyzer and cartridge lot. The test cannot diagnose von Willebrand disease alone — aPTT may be normal in type 1 von Willebrand disease. Always interpret with bleeding history, CBC, and local escalation policy.
Nursing Responsibilities
Nursing care centers on valid citrated whole blood within the stability window, honest antiplatelet documentation, paired CBC review, timely communication of closure-time patterns, and procedure-hold coordination while confirmatory testing is pending.
Before the TestDocumentation
Documentation should link closure-time patterns to medicines, CBC values, symptoms, and procedure status.
“PFA-100 drawn 0930 on citrated whole blood; delivered to lab 0945. CEPI closure time 178 s (prolonged), CADP 88 s (within reference) per coagulation comment — pattern consistent with possible aspirin effect; patient reports daily aspirin 81 mg and ibuprofen 400 mg two days ago. Platelets 198 x10^9/L, Hct 39%. Prescriber notified; dental extraction on hold pending hematology phone consult. Von Willebrand panel ordered. Patient taught to report gum bleeding, nosebleeds, or dizziness; read-back documented.”
- CEPI and CADP closure times with laboratory reference intervals
- Paired platelet count, hematocrit, and collection-to-lab time
- Antiplatelet and NSAID history documented on requisition
- Procedure hold status and prescriber or hematology notifications
- Pending von Willebrand or aggregation assays and bleeding teaching
- Specimen rejection, stability breach, or recollection plan if applicable
Patient and Family Education
Patients may fear they lack platelets when closure times are long. Use plain language tied to next tests and procedure planning, not definitive disease labels.
Platelet Function Analysis NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Platelet Function Analysis safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Platelet function analysis (PFA-100) — citrated whole blood
- Indication: 62-year-old with gum bleeding on brushing and easy bruising; PFA ordered before dental extraction in 3 days
- Timing: Specimen collected 0800; laboratory requires non-centrifuged citrate within 4 hours
- Related orders: CBC with platelet count and hematocrit; von Willebrand factor panel if CEPI/CADP prolonged; repeat PFA after aspirin hold per hematology
- Result: CEPI closure time 172 s (prolonged); CADP 92 s (within reference) — laboratory comment: pattern may reflect aspirin or mild primary hemostasis defect; confirmatory testing advised
- Trend / prior value: Prior CBC platelets 205 x10^9/L, Hct 40%; today’s draw accepted at 0835
- Pending tests: Von Willebrand factor antigen and activity; hematology consult before dental extraction
- Vital signs: HR 82/min, BP 128/76, RR 16/min, SpO₂ 98% on room air, temp 36.8°C
- Symptoms: Gum bleeding with brushing; forearm bruises; no active nosebleed
- Focused assessment: Oral mucosa with dried blood at gumline; scattered ecchymoses; alert and cooperative
- Preparation notes: Patient takes aspirin 81 mg daily; ibuprofen 200 mg two days ago for knee pain — documented on requisition; light-blue tube filled to line
- Collection events: Peripheral 21-gauge draw; specimen delivered to lab by 0840 without centrifugation
- Teaching gaps / safety concerns: Prolonged CEPI with dental extraction still scheduled; patient assumes normal CADP clears procedure without prescriber input
Answer key & rationale
Frequently Asked Questions
FAQ
What does platelet function analysis measure?
It measures closure time — how quickly platelets plug an aperture in collagen/epinephrine and collagen/ADP cartridges on a platelet function analyzer using citrated whole blood, screening primary hemostasis per RCPA and CLSI-cited laboratory guidance.
When is platelet function analysis ordered?
Common indications include unexplained bruising or mucosal bleeding, suspected von Willebrand disease or platelet dysfunction, selected preprocedure bleeding-risk assessment, and evaluation of recent aspirin exposure — always with clinical context.
What does prolonged CEPI with normal CADP suggest?
Reviewed references list mild thrombocytopenia, anemia, mild platelet dysfunction, mild von Willebrand disease, or recent aspirin or aspirin-like drugs. It does not automatically clear invasive procedures.
Do patients need to fast for PFA testing?
No special preparation is usually required for the citrated draw. Follow fasting only when other tests on the same visit require it. Many laboratories advise prescriber-guided holds of aspirin or NSAIDs before elective repeat testing.
When is PFA testing invalid?
Testing may be unreliable or not performed with low platelet count, low hematocrit, clotted or underfilled tubes, line or butterfly draws per policy, or delivery beyond the whole-blood stability window — thresholds vary by laboratory per RCPA and manufacturer guidance.
Can PFA monitor clopidogrel therapy?
Reviewed laboratory medicine references state PFA-100 has variable and often poor sensitivity to clopidogrel and other P2Y12 inhibitors — it should not be used alone to confirm or rule out P2Y12 blockade.
When should nurses escalate before PFA results return?
Escalate according to facility policy for active bleeding, large hematoma, hemodynamic change, or procedure scheduling when symptoms suggest significant bleeding risk — do not delay clinical care waiting for closure times.
References
References
-
Royal College of Pathologists of Australasia. Platelet function screen. RCPA Manual.https://www.rcpa.edu.au/Manuals/RCPA-Manual/Pathology-Tests/P/Platelet-function-screen
-
Clinical and Laboratory Standards Institute. Platelet Function Testing by Aggregometry and Other Functional Assays; Approved Guideline. CLSI document H58.https://clsi.org/standards/products/hematology/h58/
-
Favaloro EJ. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease. Thromb Res. 2020.https://doi.org/10.1016/j.thromres.2020.04.013
-
Favaloro EJ. Clinical Utility of the PFA-100. Semin Thromb Hemost. 2008.https://doi.org/10.1055/s-0029-1239098
-
MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US). Bleeding disorders.https://medlineplus.gov/bleedingdisorders.html
-
National Heart, Lung, and Blood Institute. Bleeding Disorders. Bethesda (MD): NHLBI.https://www.nhlbi.nih.gov/health/bleeding-disorders
-
Centers for Disease Control and Prevention. Bleeding Disorders in Women. Atlanta (GA): CDC.https://www.cdc.gov/ncbddd/blooddisorders/women/index.html
-
Gogstad GO; Hagen I; Korsgren M; et al. Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction. J Clin Med. 2018.https://doi.org/10.3390/jcm7090286
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Platelet Function Analysis.
Policies: Medical Review Process · Editorial Policy · Correction Policy